

Fig. 1a

BEST AVAILABLE COPY




Fig. 1b

3/25




Fig. 1c

BEST AVAILABLE COPY

4/25




Fig. 1d

5/25




Fig. 1e

BEST AVAILABLE COPY

6/25




Fig. 1f

BEST AVAILABLE COPY

7/25




Fig. 1g

BEST AVAILABLE COPY




Fig. 2a




Fig. 2b

BEST AVAILABLE COPY

10/25




Fig. 3

BEST AVAILABLE COPY




Fig. 4a

BEST AVAILABLE COPY




Fig. 4b

13/25






Fig. 4c

BEST AVAILABLE COPY




Atorvastatin




Lovastatin

Fig. 5a

15/25




Pravastatin Sodium




Fluvastatin

Fig. 5b

16/25



Mevastatin



Simvastatin

Fig. 5c




Fig. 6

BEST AVAILABLE COPY




Fig. 7

BEST AVAILABLE COPY




Fig. 8      BEG+ AVAILABLE COPY

20/25





Fig. 9a

21/25

**Statin treatment**



**CD40L staining**

**Fig. 9b**

**BEST AVAILABLE COPY**

22/25





Fig. 9c

23/25

Day 10 after Tx



Day 14 after Tx





Fig. 10

24/25

## Day 6 after onset of arthritis



## Day 12 after onset of arthritis




Fig. 11

**BEST AVAILABLE COPY**

	[ <sup>3</sup> H] Thymidine incorporation [cpm]	IFN- $\gamma$ production [pg/ml]
<b>Control</b>	13,830 ( $\pm$ 7,078)	60,112 ( $\pm$ 13,532)
<b>Low dose</b>	6,508 ( $\pm$ 6,499) *	36,368 ( $\pm$ 8,005) *
<b>High dose</b>	5,221 ( $\pm$ 7,632) *	29,805 ( $\pm$ 8,114) *

Fig. 12